BMAL1 amplitude showed a strong negative correlation with insomnia in the rucaparib group (ρ = −0.748, 95% CI [−1, 0]; p = 0.05) and positive correlation in the rucaparib after the end of therapy (ρ = 0.314, 95% CI [−0.204, 0.705]; p = 0.33). This evidence concerns the gene BMAL1 and insomnia.